Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04087720 · ClinicalTrials.gov registry record · Phase 4
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04087720 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 20 participants.
The verdict
NCT04087720, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of pegloticase on the response rate of sustained serum uric acid (sUA) reduction to sUA \< 6 mg/dL during Month 6 of treatment.
Interventions
- BIOLOGICAL Pegloticase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04087720
The ClinicalTrials.gov registry entry for NCT04087720 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegloticase is the first listed.
NCT04087720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04087720 about?
NCT04087720 is a clinical study titled "Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant". The primary objective of this study is to evaluate the effect of pegloticase on the response rate of sustained serum uric acid (sUA) reduction to sUA \< 6 mg/dL during Month 6 of treatment.
What is the current status of trial NCT04087720?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2019-09-09. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT04087720?
The interventions under investigation include: Pegloticase (BIOLOGICAL).
Who is sponsoring clinical trial NCT04087720?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.